Prot # CRAD001A USNC03T: Effects of Two Classes of Immunosuppressive Agents (mTOR Inhibitors vs. Calcineurin Inhibitors) on the Generation and Function of Human Allospecific Th1, Th17, and Treg

Project: Research project

Project Details

StatusFinished
Effective start/end date7/31/11 → 6/30/14

Funding

  • Novartis Pharmaceuticals Corporation (Prot # CRAD001A USNC03T)
View all
View less